We are live on ! Find out more
PIM

Partner Investment Management Portfolio holdings

AUM $13.9M
1-Year Est. Return 55.92%
This Fund
S&P 500
This Quarter Est. Return
+10.93%
1 Year Est. Return
+55.92%
3 Year Est. Return
+168.07%
5 Year Est. Return
+301.91%
10 Year Est. Return
–
AUM
$105M
AUM Growth
+$31M
Cap. Flow
+$23.6M
Cap. Flow %
22.35%
Top 10 Hldgs %
37.42%
Holding
105
New
22
Increased
35
Reduced
19
Closed
22

Top Buys

Rank Stock Value
1
SNNA
Sienna Biopharmaceuticals, Inc.
SNNA
+$6.61M
2
AGN.PRA
Allergan plc
AGN.PRA
+$1.98M
3
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$1.72M
4
CNC icon
Centene
CNC
+$1.44M
5
JD icon
JD.com
JD
+$1.26M

Top Sells

Rank Stock Value
1
KITE
Kite Pharma, Inc.
KITE
+$4.01M
2
UHS icon
Universal Health Services
UHS
+$1.84M
3
PCRX icon
Pacira BioSciences
PCRX
+$1.72M
4
MCK icon
McKesson
MCK
+$1.63M
5
BABA icon
Alibaba
BABA
+$1.15M

Sector Composition

Rank Sector Weight
1 Healthcare 34.37%
2 Technology 14.09%
3 Communication Services 5.97%
4 Consumer Discretionary 5.14%
5 Financials 3.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NITE
76
DELISTED
Nightstar Therapeutics plc American Depositary Shares
NITE
$103K 0.1%
+5,350
New +$116K
VYGR icon
77
Voyager Therapeutics
VYGR
$189M
$100K 0.09%
4,844
-11,573
-70% -$131K
KITE
78
DELISTED
Kite Pharma, Inc.
KITE
$14K 0.01%
79
-28,758
-100% -$4.01M
AAPL icon
79
Apple
AAPL
$4.51T
– –
-11,820
Closed -$426K
AMT icon
80
American Tower
AMT
$77.8B
– –
-5,084
Closed -$673K
BIIB icon
81
Biogen
BIIB
$30.8B
– –
-248
Closed -$67K
BKNG icon
82
Booking.com
BKNG
$160B
– –
-4,400
Closed -$329K
BMRN icon
83
BioMarin Pharmaceuticals
BMRN
$11.6B
– –
-3,973
Closed -$361K
BTU icon
84
Peabody Energy
BTU
$2.77B
– –
-2,244
Closed -$55K
CHRS icon
85
Coherus Oncology
CHRS
$228M
– –
-24,236
Closed -$348K
HRTX icon
86
Heron Therapeutics
HRTX
$95.8M
– –
-49,038
Closed -$679K
LBTYA icon
87
Liberty Global Class A
LBTYA
$3.59B
– –
-25,550
Closed -$821K
MCK icon
88
McKesson
MCK
$99.6B
– –
-9,888
Closed -$1.63M
MRVL icon
89
Marvell Technology
MRVL
$193B
– –
-26,626
Closed -$440K
PBYI icon
90
CALL
Puma Biotechnology
PBYI
$406M
– –
-4,800
Closed -$420K
PCRX icon
91
Pacira BioSciences
PCRX
$957M
– –
-36,119
Closed -$1.72M
RGNX icon
92
Regenxbio
RGNX
$675M
– –
-4,824
Closed -$95K
UHS icon
93
Universal Health Services
UHS
$10.4B
– –
-15,117
Closed -$1.84M
XLV icon
94
CALL
State Street Health Care Select Sector SPDR ETF
XLV
$42.1B
– –
-34,800
Closed -$2.76M
CSOD
95
DELISTED
Cornerstone OnDemand, Inc.
CSOD
– –
-2,313
Closed -$83K
MDCO
96
CALL
DELISTED
Medicines Co
MDCO
– –
-21,300
Closed -$810K
ALDR
97
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-15,296
Closed -$175K
EVHC
98
DELISTED
Envision Healthcare Holdings Inc
EVHC
– –
-2,100
Closed -$132K
RXDX
99
DELISTED
Ignyta, Inc.
RXDX
– –
-19,254
Closed -$199K
SPNC
100
DELISTED
Spectranetics Corp
SPNC
– –
-15,056
Closed -$578K
1 2 3
4

Similar funds

SWM
Sequoia Wealth Management Hoffman Estates, Illinois $12.9M AUM 25.75% 1-Year Est. Return
ACM
ADI Capital Management New York $17.5M AUM 49.32% 1-Year Est. Return
ECAU
Everett Capital Advisors (UK) London, United Kingdom $18.6M AUM 22.81% 1-Year Est. Return
SL
Signition LP New York $20M AUM 28.26% 1-Year Est. Return
DII
Domini Impact Investments New York $7.59M AUM 47.68% 1-Year Est. Return
FIM
FourPoints Investment Managers Paris, France $21.1M AUM 11.11% 1-Year Est. Return
EM
Emancipation Management New York $22.4M AUM 18.33% 1-Year Est. Return
BHC
Balch Hill Capital San Francisco, California $22.8M AUM

Partner Investment Management's Q3 2017 Portfolio in Review

As of Q3 2017, Partner Investment Management held 105 positions worth $105M, up 42% from $74.4M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Partner Investment Management deployed $23.6M of net new capital in Q3 2017, opening 22 new positions and adding to 35 existing holdings. Its largest new stake was Sienna Biopharmaceuticals, Inc.: 300,940 shares worth $6.7M.

By sector, the portfolio is most concentrated in Healthcare at 34% of assets, down from 39% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Kite Pharma, Inc., an estimated $4.01M trimmed.

  • Partner Investment Management's largest Q3 2017 buy was Sienna Biopharmaceuticals, Inc.: 300,940 shares worth $6.7M.
  • Partner Investment Management added most to Portola Pharmaceuticals, Inc. in Q3 2017, an estimated $1.72M increase.
  • Partner Investment Management's biggest Q3 2017 reduction was Kite Pharma, Inc., cutting an estimated $4.01M.
  • Partner Investment Management fully exited Universal Health Services in Q3 2017, selling an estimated $1.84M.
  • Partner Investment Management's ten largest holdings make up 37% of its $105M portfolio in Q3 2017.
  • Partner Investment Management opened 22 new positions and closed 22 in Q3 2017.
  • Partner Investment Management's portfolio value rose 42% quarter-over-quarter to $105M.

Based on Partner Investment Management's 13F filing for Q3 2017, filed 14 Nov 2017.